Forge Biologics Announces $90 Million Series C Financing to Expand Client Offerings and Add Services to Enhance End-to-End Gene Therapy Manufacturing Platforms
Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced that it has raised $90 million in a Series C financing, bringing its total funding raised to date to $330 million. The current round was co-led by Drive Capital and Aisling Capital with an additional undisclosed strategic investor.
“We continue our ambitious mission to enable access to life changing gene therapies by fulfilling a key goal of bringing them from concept to reality,” said Timothy J. Miller, Ph.D., CEO, President, and Co-Founder of Forge Biologics. “To deliver on that mission, we’ve made great strides in our facility development, technology advancement, and hiring expansion. These new funds will help support this next measured phase of our growth focused on delivering new services to our clients so that we can support them from idea to impact. Each advancement we make goes towards serving our clients and their patient communities, and we are grateful to our investors for their confidence in our mission.”
The Company will use the funding to expand client offerings, including proprietary technologies, manufacturing systems, cell lines, and additional services to bolster its end-to-end manufacturing platform. Through the Company’s 200,000 square foot cGMP facility dedicated to AAV viral vector manufacturing, Forge will expand the number of offerings available to clients to help scale gene therapy programs from research to clinical and commercial manufacturing in its 20 cGMP suites utilizing its operational 50L, 500L, 1,000L and 5,000L bioreactors.
“Forge has grown tremendously over the last two years, hiring experienced talent and scaling the facility, technology, and client offerings according to their unique hybrid business model,” said Molly Bonakdarpour, General Partner at Drive Capital. “We believe that Forge is becoming an established leader in gene therapy manufacturing, consistent with Drive Capital’s focus to build and support market-defining companies.”
“We have confidence in the caliber of leadership at Forge, their technical expertise at all levels, and the meticulous attention to detail in every facet of the business,” said Andrew Schiff, M.D., Managing Partner at Aisling Capital. “The gene therapy industry has been constrained by technical, operational, and capacity constraints, and Forge is poised to tackle each of those areas to alleviate the manufacturing bottleneck as they set out to do.”
Recent Milestones Reached
- Hired notable talent for key technical roles with gene therapy-specific expertise: Agnieszka Gornicka, Ph.D., Director, GMP Manufacturing; Ganesh Krishnamoorthy, Associate Director, Process Development
- Scaled the Company’s proprietary HEK 293 suspension platform process from 50L to 1000L
- Integrated new systems into its platform process such as single-use chromatography and automated fill-finish
- Increased overall manufacturing footprint to over 200,000 square feet; buildout includes 20 cGMP suites utilizing 50L, 500L, 1,000L, and 5,000L bioreactors, with additional cGMP suites planned
- Formed an independent board of preeminent experts, a Scientific and Manufacturing Advisory Board (SMAB), to advise the Company on its gene therapy manufacturing offerings and therapeutics pipeline development with a distinct and strategic emphasis on manufacturing advancements
About Forge Biologics
Forge Biologics is a hybrid gene therapy contract manufacturing and clinical-stage therapeutics development company. Forge’s mission is to enable access to life changing gene therapies and help bring them from idea to reality. Forge’s 200,000 square foot facility utilizes 20 cGMP suites in Columbus, Ohio, the Hearth, to serve as its headquarters. The Hearth is a custom-designed cGMP facility focused on AAV manufacturing and can host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most. To learn more, visit www.forgebiologics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Senior Manager, Marketing and Communications
Senior Vice President, Finance and Investor Relations
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IEEE Announces Decision on Its Standards-related Patent Policy30.9.2022 18:31:00 CEST | Press release
The IEEE Standards Association Board of Governors (IEEE SA BOG) took action to update the Patent Policy for IEEE standards development, which will go into effect 01 January 2023. These updates are intended to improve the clarity of IEEE’s standards processes related to patented technologies, while offering more options for stakeholders. In accordance with IEEE SA’s policies and procedures, the following resolutions were approved by consensus without objections by the full IEEE SA BOG. The IEEE SA BOG approved proposed updates to the IEEE SA Standards Board Bylaws, effective 01 January 2023. The IEEE SA BOG approved proposed updates to the IEEE SA Letter of Assurance (LOA) form, effective 01 January 2023. The IEEE SA BOG approved proposed updates to the patent policy FAQs, effective 01 January 2023. For the same IEEE standard, in instances where there is one Submitter of an Accepted LOA under the 2015 policy and another Submitter of an Accepted LOA under a subsequent policy or using the
Calling All Sake Aficionados! October 1st Is "Sake Day." Let's Kampai Together!! (Kampai Means "Toast" in Japanese)30.9.2022 16:00:00 CEST | Press release
There are countless events around the world celebrating the delights of wine and beer; October 1st is known as "Sake Day," where sake lovers worldwide gather, enjoy, and appreciate this delicious beverage. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220929005349/en/ toast (Photo: Business Wire) Sake Day was set as October 1st by the Japan Sake and Shochu Makers Association (JSS), the largest sake industry organization in Japan with members consisting of some 1,700 producers of sake, Honkaku Shochu, Awamori, and Hon-Mirin. This date was selected because October 1st marked the beginning of the new brewing season using freshly harvested rice crops. Events celebrating sake have been planned worldwide for Sake Day on October 1st. In Japan, the "Kampai! with Sake Week" event will run for ten days around Sake Day on October 1st, where JSS, prefectural sake organizations, breweries, restaurants, liquor stores, and sake lovers wil
Alkegen Launching Trio of New High Efficiency Filtration Products for Air, Liquid and Molecular Applications30.9.2022 14:30:00 CEST | Press release
Alkegen, a leading specialty materials platform that provides high performance materials used in advanced applications, announced they will be launching three new High Efficiency Filtration (HEF) products during their exhibition at the upcoming World Filtration Congress in San Diego, CA. These are the first new filtration products launched under the Alkegen brand name since the merger of Lydall and Unifrax last October. “This trio of HEF media – one for air, one for liquid, one for molecular applications – represents the first wave of advanced materials developed and released under our new Alkegen filtration product development team. These launches combine Lydall’s well-known filtration and manufacturing expertise with Unifrax’s proven, rapid innovation capabilities,” said Paul Vallis, President of the Filtration & Catalysis Group. “This is the first of many innovations we expect to deliver as our portfolio evolves to meet the continuous demand for ever-higher efficiency and reduced en
Nexign’s Article Included in TM Forum’s Benchmark Report30.9.2022 13:12:00 CEST | Press release
Nexign, a leading provider of BSS and digitalization solutions, announces that its article has been included in TM Forum’s benchmark report “Telco Revenue Growth: Taking It to the Next Level”. The report investigates the primary sectors and services affecting communications service providers (CSPs) and the areas of growth and decline. It draws on research collected from 33 of the world’s largest operators and serves as a source of valuable information about factors influencing successful telco-to-techco transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220930005236/en/ Nexign’s Article Included in TM Forum’s Benchmark Report (Photo: Business Wire) Nexign’s article “Harnessing Traditional and New Revenue Streams on Track to Maturity: Harmonization of the BSS Core” discusses key challenges faced by modern CSPs while shifting beyond traditional communications and exploring vertical markets. The authors state that o
The Estée Lauder Companies Launches 2022 Breast Cancer Campaign to Honor 30 th Anniversary and Positively Impact the Global Breast Cancer Community30.9.2022 12:45:00 CEST | Press release
In the 30 years since Evelyn H. Lauder launched The Estée Lauder Companies’ Breast Cancer Campaign (The Campaign) and co-created the Pink Ribbon in 1992, The Campaign’s mission to help create a breast cancer-free world for all has remained steadfast. The Estée Lauder Companies (ELC) has a long-standing commitment to helping women and girls achieve their highest potential. As ELC’s largest corporate social impact program, The Campaign is a cornerstone of ELC’s social investments in women’s advancement and health, uniting people everywhere to positively impact the global breast cancer community. As breast cancer is the most commonly diagnosed cancer in the world,1 ELC's continued commitment to improving the lives of all those touched by the disease remains unwavering. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220930005040/en/ The Estée Lauder Companies Launches 2022 Breast Cancer Campaign (Graphic: Business Wire) Together
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom